Myopathy Associated With Statins and SGLT2 – A Review of Literature
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Myopathy Associated With Statins and SGLT2 – A Review of Literature
Authors
Keywords
-
Journal
CURRENT PROBLEMS IN CARDIOLOGY
Volume 46, Issue 4, Pages 100765
Publisher
Elsevier BV
Online
2020-12-12
DOI
10.1016/j.cpcardiol.2020.100765
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
- (2020) Sanjay Kalra et al. Diabetes Therapy
- Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report
- (2020) Eugene Brailovski et al. ANNALS OF INTERNAL MEDICINE
- The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review
- (2020) Chen-Ning Wu et al. Journal of Diabetes Research
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes
- (2019) Hiroyasu Mori et al. Journal of Diabetes Investigation
- Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
- (2019) A.J. Scheen DIABETES & METABOLISM
- Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study
- (2019) Zeeshan Javed et al. CLINICAL ENDOCRINOLOGY
- Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence
- (2019) Niki Katsiki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus
- (2019) Noriko Ogama et al. Journal of Clinical Medicine
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
- (2019) Megumi Yasuda et al. Journal of Diabetes Investigation
- Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials
- (2019) Fang-Hong Shi et al. Frontiers in Pharmacology
- Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study
- (2019) Yi Tang et al. Nutrition & Diabetes
- Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence
- (2018) Liam R Brunham et al. CARDIOVASCULAR RESEARCH
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study
- (2018) Yuya Tsurutani et al. DIABETES OBESITY & METABOLISM
- SGLT inhibitor adjunct therapy in type 1 diabetes
- (2018) Rory J. McCrimmon et al. DIABETOLOGIA
- Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors
- (2018) Toshiyuki Sakaeda et al. International Journal of Medical Sciences
- Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
- (2018) Seigo Sugiyama et al. Journal of Atherosclerosis and Thrombosis
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
- (2018) Matthew C. Riddle et al. DIABETES CARE
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis
- (2017) Julie Refardt et al. International Journal of Endocrinology
- In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin
- (2016) Rao N. V. S. Mamidi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Statin-Associated Autoimmune Myopathy
- (2016) Andrew L. Mammen NEW ENGLAND JOURNAL OF MEDICINE
- Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review
- (2016) Lluis Campins et al. PHARMACOLOGY
- Increased grip strength with sodium-glucose cotransporter 2
- (2016) Motoaki Sano et al. Journal of Diabetes
- New drugs: Empagliflozin
- (2015) Australian Prescriber
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events
- (2015) Daisuke Yabe et al. Expert Opinion On Drug Safety
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials
- (2015) Maciej Banach et al. PHARMACOLOGICAL RESEARCH
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care
- (2013) Marianne K. DeGorter et al. Circulation-Cardiovascular Genetics
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes: The Korean Sarcopenic Obesity Study (KSOS)
- (2010) T. N. Kim et al. DIABETES CARE
- Drug-related Myopathies of Which the Clinician Should Be Aware
- (2010) Ritu Valiyil et al. Current Rheumatology Reports
- Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression
- (2009) Vito Iacobazzi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Toxic and drug-induced myopathies
- (2009) M C Dalakas JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Is There A Relationship Between Insulin Resistance and Frailty Syndrome?
- (2008) Giuseppe Paolisso et al. CURRENT PHARMACEUTICAL DESIGN
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search